SG Americas Securities LLC Boosts Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

SG Americas Securities LLC raised its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 81.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 99,221 shares of the company’s stock after buying an additional 44,686 shares during the period. SG Americas Securities LLC’s holdings in Lyell Immunopharma were worth $192,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC boosted its position in Lyell Immunopharma by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 82,956 shares of the company’s stock valued at $161,000 after buying an additional 21,036 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in Lyell Immunopharma by 109.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock valued at $40,000 after buying an additional 14,229 shares during the last quarter. Citigroup Inc. boosted its position in Lyell Immunopharma by 20.0% in the 3rd quarter. Citigroup Inc. now owns 193,739 shares of the company’s stock valued at $285,000 after buying an additional 32,225 shares during the last quarter. American Century Companies Inc. boosted its position in Lyell Immunopharma by 51.0% in the 3rd quarter. American Century Companies Inc. now owns 120,951 shares of the company’s stock valued at $178,000 after buying an additional 40,833 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in Lyell Immunopharma by 20.1% in the 3rd quarter. Deutsche Bank AG now owns 72,322 shares of the company’s stock valued at $106,000 after buying an additional 12,100 shares during the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut their target price on shares of Lyell Immunopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th.

Lyell Immunopharma Stock Performance

Shares of Lyell Immunopharma stock opened at $3.01 on Friday. The firm has a market cap of $764.83 million, a PE ratio of -3.24 and a beta of -0.56. The firm’s 50-day simple moving average is $2.23 and its 200-day simple moving average is $1.99. Lyell Immunopharma, Inc. has a 1 year low of $1.32 and a 1 year high of $3.97.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, February 28th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. On average, equities analysts predict that Lyell Immunopharma, Inc. will post -0.91 earnings per share for the current year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.